Image by Racool_studio on Freepik
Researchers from Swansea University have discovered that a medication frequently used to treat type 2 diabetes may also be effective in treating autoimmune diseases.
Researchers at the University’s Faculty of Medicine, Health, and Life Sciences have discovered that the medication canagliflozin, also known as Invokana, may be used to treat autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis because it targets T-cells, a vital immune system component. Canagliflozin is a medication that lowers blood sugar levels in persons with type 2 diabetes, but researchers have discovered that it also has an unanticipated effect on the immune system.
Targeting T-cell metabolism in autoimmune disease has been shown to have therapeutic advantages. T-cells are a type of white blood cell that aids in the body’s defense against infections and sickness, but they have been seen to assault healthy tissues in autoimmune diseases.
Canagliflozin dampens T-cell activation, according to a recent study that was published in the journal Cell Metabolism. This finding raises the possibility that the medication could be used to treat T-cell-driven autoimmunity.
Dr. Nick Jones, senior author who led the study said, “Our findings are significant as they provide the foundation for the clinical development of canagliflozin for the treatment of certain autoimmune diseases. As the drug is already widely used and has a known safety profile in humans, it could potentially reach clinic quicker than any new drugs developed and bring valuable benefits more swiftly to patients with autoimmune disorders.”
Ben Jenkins, first author and postdoctoral researcher at Swansea said, “Identifying new roles for drugs that are currently being used in other disease settings is an exciting area of research. Given that our research primarily targets the metabolism of immune cells, we hope that the potential therapeutic benefits of our findings are applicable to a wide range of conditions.”
Canagliflozin may one day be tested in a clinical setting for the treatment of specific autoimmune diseases, according to the researchers.
more recommended stories
Action Video Games and Brain Health: Study InsightsGaming and Brain Structure: What MRI.
Creatine May Boost Muscle Strength in Alzheimer’s PatientsCreatine Supplementation Shows Promise in Alzheimer’s.
New Drug STF-1623 Shows Promise in Treating Solid TumorsSTF-1623 Transforming ‘Cold’ Tumors into ‘Hot’.
Macrophage Microautophagy Supports Immune ReadinessA Breakthrough in Cellular Recycling Macrophages,.
The Role of α-Glucosidase in Type 2 Diabetesα-Glucosidase Inhibition: Functional Food Compounds for.
Oral Bacteria Linked to AtherosclerosisNew Evidence Links Viridans Streptococci to.
CDI Test Shows Early Detection Potential in Alzheimer’sBreakthrough Study Highlights Brain Blood Flow.
Prenatal Chlorpyrifos Exposure and Pediatric Brain ChangesA Growing Concern in Pediatric Neurodevelopment.
Valve Deterioration After TAVI: New Research InsightsThe Growing Role of TAVI in.
FAST Walking Shows Promise in Post-Stroke RehabStroke remains one of the leading.
Leave a Comment